-

Autobahn Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, and Will Stratton, Chief Business Officer, will participate in the 25th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Mr. Finney and Mr. Stratton will present on Wednesday, April 15, 2026, at 11:00 a.m. ET and participate in 1x1 meetings with investors.

About Autobahn Therapeutics
Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neuroimmunologic clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by elunetirom (ABX-002), a CNS thyroid hormone receptor (CNS-TR) agonist being developed as a potential adjunctive treatment for people with major depressive disorder and bipolar disorder depression. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Investors:
Alex Straus, THRUST
alex@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Investors:
Alex Straus, THRUST
alex@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics Reports AMPLIFY-BD Results for Elunetirom in Bipolar Depression, Highlighting Rapid, Robust, and Sustained Improvements in Depressive Symptoms and Functioning

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that full results from its Phase 2 AMPLIFY-BD trial were presented at Psych Congress 2026, which took place September 15-19 in New Orleans, Louisiana. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, achieved clinically meaningful benefit and statistical significance acros...

Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons...

Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression, a disorder affecting approximately 7 million adults in the U.S. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, ac...
Back to Newsroom